Careers
In the treatment of rare and serious eye disease, COME SEE WHAT WE'RE SEEING
In the treatment of rare and serious eye disease,Come see what we're seeing KALA Pharmaceuticals is now KALA BIO

KALA BIO is a clinical-stage biopharmaceutical company on a mission.

Guided by advanced science, we’re focused on solving rare and serious eye diseases through research and development of innovative therapies.

KALA BIO is a leader in the emerging field of mesenchymal stem cell secretome (MSC-S) therapy. Using our proprietary MSC-S platform, we are developing therapies with regenerative healing effects for rare ocular surface and retinal diseases, with the ultimate goal of preserving vision and changing lives.

Learn about our
innovative technology

Utilizing our proprietary MSC-S platform, KALA BIO is developing therapies to treat rare and severe eye diseases.

KPI-012

for Rare Ocular
Surface Diseases

KPI-012 has received Orphan Drug and Fast Track Designation from the FDA for PCED.

A topical therapy currently in a Phase 2b clinical study for persistent corneal epithelial defect (PCED). KPI-012 is also being evaluated for clinical development in other rare ocular surface diseases, including limbal stem cell deficiency.

Positive results from the current Phase 2b study could serve as the first of two required trials to support BLA submission.
KPI-012 has received Orphan Drug and Fast Track Designation from the FDA for PCED.
Positive results from the current Phase 2b study could serve as the first of two required trials to support BLA submission.

Interested in participating in
our
ongoing PCED clinical trial?

Contact KALA BIO

KPI-014

Program for
Rare Inherited
Retinal Disease

An intravitreal therapy, in preclinical development, to provide a gene-agnostic approach for the treatment of of inherited retinal degenerations and other back of the eye diseases.

We are developing treatments that strive to change the lives of patients with rare, sight-threatening diseases. 

BLA, Biologics License Application.

Come see our pipeline

Bringing leadership and vision to the treatment of rare ophthalmic diseases

KALA BIO is an innovator in ophthalmic therapy, having developed and secured FDA approval for two opthalmic products: EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25%, for the short-term treatment of dry eye disease, and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%, for the treatment of pain and inflammation following ocular surgery. In July 2022, KALA BIO announced the completion of the sale of its commercial products to Alcon Inc. With its new focus on biologics, KALA BIO continues its commitment to improving vision and improving lives.

Meet our leadership team